Business Context and Reporting Period
This Form 8-K Current Report was filed by 180 Life Sciences Corp. (not Forum Markets Inc.) on August 15, 2023, covering events occurring on August 9, 2023. The company, a Delaware corporation, announced the entry into a material definitive agreement for a registered public offering of securities.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $3.0 million.
- Net Proceeds: Approximately $2.6 million after deducting placement agent fees and estimated offering expenses.
- Securities Issued:
- 666,925 shares of Common Stock at $0.65 per share.
- 3,948,460 Pre-Funded Warrants at $0.6499 per warrant (exercise price $0.0001).
- 4,615,385 Common Warrants (exercise price $0.65, expiring October 10, 2028).
- Placement Agent Fees: 6.0% of gross proceeds from Shares and Pre-Funded Warrants, plus expense reimbursement up to $115,000.
Material Changes and Agreements
The filing details a significant capital raise and related contractual obligations:
- Use of Proceeds: Funds are designated for research and development, general corporate purposes, legal expenses, and the preparation of a marketing authorization application for Dupuytren's Contracture in the United Kingdom and potentially the United States.
- Lock-Up Agreements: Directors and executive officers agreed not to sell or transfer company securities for 90 days following the closing of the offering.
- Issuance Restrictions: The company agreed not to conduct any issuances of Common Stock for 90 days or enter into variable rate transactions for six months following the closing.
- Warrant Amendment: Existing warrants held by the Institutional Investor were amended to set a uniform exercise price of $0.83 per share.
Outlook, Risks, and Management Commentary
Management intends to utilize the net proceeds to advance clinical and regulatory milestones for its lead asset, Dupuytren's Contracture. The offering closed on August 14, 2023. The filing notes customary representations, warranties, and indemnification obligations but does not explicitly list new material risks beyond standard offering terms. The company is not an emerging growth company.
Key Facts for Investor Verification
- Verify the actual closing date and final net proceeds received, as the filing states "expected" amounts.
- Confirm the dilution impact of the 4.6 million Common Warrants and 3.9 million Pre-Funded Warrants on existing shareholders.
- Review the specific terms of the Warrant Amendment Agreement regarding the $0.83 exercise price for existing warrants.
- Monitor the company's progress on the marketing authorization application for Dupuytren's Contracture as the primary use of funds.
- Check for any subsequent filings regarding the 90-day lock-up expiration for insiders.